CRISPR Therapeutics (NasdaqGM:CRSP) has announced a $350 million offering of convertible senior notes. The securities are a ...

Lipid nanoparticles, or LNPs, best known as the delivery vehicle for the COVID-19 mRNA vaccines received by billions of people, are now at the center of a much larger medical revolution. Researchers ...

CRISPR Therapeutics AG (Nasdaq: CRSP) (the “Company”) today announced the pricing of $550 million aggregate principal amount of its convertible senior notes due 2031 (the “notes”) in a private ...

ARK Invest purchased ~281K CRISPR Therapeutics (CRSP) shares worth $14.82M after a 10% drop triggered by a $350M private offering announcement.

瑞士楚格和波士顿 - CRISPR Therapeutics AG (NASDAQ:CRSP) 今日宣布,在面向合格机构买家的私募发行中,定价发行5.5亿美元2031年到期的可转换优先票据,根据新闻稿声明。

CRISPR Therapeutics (CRSP) upsized a $550M convertible notes deal due 2031 at 1.125%, with a 45% conversion premium—get the key terms now.

Current shareholders were thrown an unexpected curveball that they actually should have been expecting.

The $550 million convertible senior notes offering was upsized from a previously announced offering of $350 million.

Cathie Wood’s ARK Invest added to several beaten-down technology and biotech names while trimming positions elsewhere. The investment manager made a notable purchase in gene-editing company CRISPR ...

Discover how CRISPR-based therapy could revolutionize HPAI treatment in poultry, offering farmers a lifesaving alternative to complete flock depopulation and preventing costly outbreaks.

In a smaller yet noteworthy trade, ARK purchased 25,000 shares of the 3iQ Solana Staking ETF (SOLQ), with a total value of $173,042. This acquisition reflects ARK’s interest in the growing ...

Swiss–American biotech CRISPR Therapeutics (Nasdaq: CRSP) today announced the pricing of $550 million in convertible senior notes due in 2031. The notes are being offered in a private offering to ...